Compare Archer Aviation Inc (ACHR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer Aviation Inc vs Recursion Pharmaceuticals Inc — how do they compare? Archer Aviation Inc trades at $4.84 (market cap $3.76B), while Recursion Pharmaceuticals Inc trades at $3.68 (market cap $2.04B). The key difference: Archer Aviation Inc is the larger of the two by market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Archer Aviation Inc nearer its low. Which is the better fit depends on your goals.
| ACHR | RXRX | |
|---|---|---|
Market Cap | $3.76B | $2.04B |
Sector | Industrials | Health |
52-Week High | $13.64 | $6.79 |
52-Week Low | $4.68 | $2.84 |
Enterprise Value | $2.11B | $1.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $5.37, up 7.83% with a bearish technical signal despite recent momentum. The company shows severe financial strain with -$618.2M net income on minimal $300K revenue in 2025, though analyst sentiment remains optimistic with 78% buy ratings. Recent news highlights progress toward FAA certification for its Midnight eVTOL aircraft, with commercialization targeted for 2028 and a $6B order book providing long-term potential.
The stock presents high-risk speculative potential with significant execution hurdles. While regulatory progress and major partnerships with United Airlines and Stellantis support the bullish case, persistent cash burn and negative margins require substantial capital raises. Investors face binary outcomes dependent on successful certification and commercial deployment timelines against intense competition in the emerging eVTOL market.
RXRX trades at $3.96, up 4.21% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows improving quarterly EPS beats but faces deep losses with a -851.51% net margin. Recent news highlights its AI-driven drug discovery platform and inclusion in Cathie Wood's portfolio (The Motley Fool, 2026-07-05).
Analyst consensus is mixed with 40% buy ratings and a $7.83 price target suggesting significant upside, but high cash burn and negative profitability pose substantial risks. Investment appeal hinges on successful clinical advancements offsetting current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer Aviation Inc
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
